Table 4.
Levels of biomarkers of thyroid function, taking TAS2R3/4 diplotype and papillary thyroid carcinoma phenotype into account.
| TT3 (ng/mL) | FT4 (ng/dL) | TSH (μIU/mL) | Tg (ng/mL) | |||||
|---|---|---|---|---|---|---|---|---|
| N | Mean (SE) | N | Mean (SE) | N | Mean (SE) | N | Mean (SE) | |
| All subjects | ||||||||
| TC/TC | 95 | 1.13 (0.02) | 95 | 1.31 (0.02) | 95 | 2.13 (0.13) | 55 | 24.98 (7.36) |
| TC/CG | 77 | 1.17 (0.02) | 77 | 1.30 (0.02) | 77 | 2.81 (0.28) | 47 | 14.92 (2.97) |
| CC/TC | 17 | 1.04 (0.03) | 17 | 1.29 (0.05) | 17 | 2.30 (0.29) | 7 | 20.50 (3.75) |
| CG/CG | 15 | 1.19 (0.05) | 15 | 1.26 (0.04) | 15 | 2.69 (0.63) | 8 | 17.50 (3.66) |
| CC/CG | 6 | 1.14 (0.05) | 6 | 1.26 (0.09) | 6 | 2.02 (0.68) | 1 | 4.75 |
| CC/CC | 1 | 0.70 | 1 | 1.47 | 1 | 1.14 | — | — |
| Pa | 0.05 | 0.613 | 0.652 | 0.24 | ||||
| */* | 187 | 1.16 (0.01) | 187 | 1.30 (0.01) | 187 | 2.45 (0.14) | 110 | 20.14 (3.91) |
| CC/** | 23 | 1.04 (0.03) | 24 | 1.29 (0.04) | 24 | 2.18 (0.26) | 8 | 18.53 (3.80) |
| Pb | 0.005 | 0.803 | 0.536 | 0.364 | ||||
| Controls | ||||||||
| TC/TC | 50 | 1.12 (0.02) | 50 | 1.28 (0.03) | 50 | 2.40 (0.20) | 25 | 19.01 (4.39) |
| TC/CG | 40 | 1.17 (0.03) | 40 | 1.29 (0.02) | 40 | 2.59 (0.33) | 25 | 12.19 (2.04) |
| CC/TC | 8 | 1.03 (0.04) | 8 | 1.28 (0.06) | 8 | 2.88 (0.44) | 4 | 25.47 (3.84) |
| CG/CG | 8 | 1.15 (0.08) | 8 | 1.18 (0.07) | 8 | 3.65 (1.16) | 4 | 23.33 (3.66) |
| CC/CG | 3 | 1.10 (0.06) | 3 | 1.21 (0.10) | 3 | 1.80 (0.79) | 1 | 4.75 |
| CC/CC | 1 | 0.70 | 1 | 1.47 | 1 | 1.14 | — | — |
| Pa | 0.159 | 0.327 | 0.496 | 0.084 | ||||
| */* | 98 | 1.14 (0.02) | 98 | 1.27 (0.02) | 98 | 2.57 (0.19) | 55 | 16.30 (2.26) |
| CC/** | 12 | 1.02 (0.04) | 12 | 1.28 (0.05) | 12 | 2.47 (0.38) | 5 | 21.32 (5.10) |
| Pb | 0.022 | 0.996 | 0.974 | 0.317 | ||||
| Cases | ||||||||
| TC/TC | 45 | 1.15 (0.03) | 45 | 1.34 (0.03) | 45 | 1.84 (0.15) | 30 | 29.95 (13.02) |
| TC/CG | 37 | 1.18 (0.03) | 37 | 1.31 (0.03) | 37 | 3.04 (0.45) | 22 | 18.04 (5.93) |
| CC/TC | 9 | 1.04 (0.06) | 9 | 1.30 (0.07) | 9 | 1.78 (0.32) | 3 | 13.87 (5.51) |
| CG/CG | 7 | 1.24 (0.07) | 7 | 1.31 (0.05) | 7 | 1.73 (0.21) | 3 | 7.77 (2.13) |
| CC/CG | 3 | 1.20 (0.10) | 3 | 1.34 (0.20) | 3 | 2.24 (1.28) | — | — |
| Pa | 0.159 | 0.651 | 0.179 | 0.408 | ||||
| */* | 89 | 1.17 (0.02) | 89 | 1.32 (0.02) | 89 | 2.33 (0.21) | 55 | 23.98 (7.49) |
| CC/** | 11 | 1.07 (0.25) | 12 | 1.30 (0.06) | 12 | 1.90 (0.36) | 3 | 13.87 (5.51) |
| Pb | 0.111 | 0.739 | 0.415 | 0.933 | ||||
TT3, total triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone; Tg, thyroglobulin, analysed only for anti-thyroglobulin antibody-negative subjects; N, number of subjects; SE, standard error. aP-values come from the generalized linear models adjusted for family history of thyroid cancer (diplotype groups with fewer than 5 subjects were excluded from the comparison because of the rarity). bP-values come from Student’s t-tests between diplotype groups (diplotypes with the CC haplotype versus all other diplotypes).